Navigation Links
Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
Date:7/7/2008

V."

Steve Worland, Ph.D., Anadys' President and CEO, commented, "The decision to take ANA773 into HCV, which will be our third clinical development program to commence dosing this year, reflects an expansion of Anadys' development efforts in HCV. As an approach to treat hepatitis C, the TLR7 mechanism is independent from, and potentially complementary to, ANA598, Anadys' non-nucleoside HCV polymerase inhibitor currently in Phase I clinical development." Commenting on the expected impact this expansion will have on the Company's cash outlook for 2008, Dr. Worland added, "Because the ANA773 hepatitis C program is highly leveraged off our oncology program, we expect to carry forward all three clinical development programs this year within our previous 2008 cash utilization projection of $29 to $31 million."

ANA773 Phase I Clinical Trial in HCV

The Phase I clinical trial of ANA773 in HCV will be conducted under a two-part protocol. Part A of the study will include both single and multiple doses of ANA773 in healthy volunteers. Successive cohorts of volunteers will receive ascending dose levels of ANA773. The primary objectives of Part A of the study are to assess safety and tolerability. In Part B of the study, HCV patients will receive ANA773 every other day for 28 days. The primary objectives of Part B are to assess safety, tolerability and viral load decline. The starting dose level in HCV patients will be selected based on safety, tolerability and immune responses seen in healthy volunteers in Part A. It is expected that this study design will allow initial dosing in HCV patients at a dose that will have demonstrated a desired magnitude of immune stimulation in the healthy subjects, and that dosing in patients will initiate prior to completion of dose escalation in Part A of the study. Approximately 40 healthy volunteers and 24 patients are anticipated to be enrolled in this study. Dosing is expected to begin in healthy volunteers within the nex
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
2. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
3. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
7. Isis Pharmaceuticals Conference Call Notice
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio ... acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... of the acquisition were not disclosed. Progressive ... a wide range of sleep, mobility, and respiratory products to ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a ... Leesburg, Virginia is the first in ... chamber. Dr. Susan M. Barnes , Medical ... Barnes and husband, Dr. Cole Taylor , are avid scuba ...
(Date:1/14/2014)... 14, 2014 NineSigma , Inc., the leading ... Innovation Leadership Summit , May 14-16, 2014 at the ... Ohio . This is the ... to breakthrough achievements through open innovation. Participants will learn ...
Breaking Medicine Technology:Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... 3, 2007 - Xanthus,Pharmaceuticals, Inc today presented ... pathological signs of chronic,disease in an animal ... by Stephen J. Karlik, Ph.D., Professor of ... London, Ontario,together with researchers from Xanthus in ...
... Announces Positive Data in Nonclinical (IND) In- ... May 3, 2007 (PRIME NEWSWIRE) -- Samaritan,Pharmaceuticals ... pleased to announce positive results were attained ... well recognized in-vitro models. , Although nonclinical ...
Cached Medicine Technology:Xanthus Presents Novel Approach for Autoimmune Disease Reversal,with Symadex 2Xanthus Presents Novel Approach for Autoimmune Disease Reversal,with Symadex 3Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro,Studies for Promising Alzheimer's Drug 2Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro,Studies for Promising Alzheimer's Drug 3
(Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
(Date:4/17/2014)... the April issue of Experimental Biology and ... Drs. Rex Gaskins and Paul Kenis in the ... of the University of Illinois Urbana-Champaign describe their ... reactions underlie a variety of cell functions including ... these crucial roles in regulating normal cellular behavior, ...
(Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2
... Praxis(R) EMR was named,the top EMR in the 2008 ... Physicians, (AAFP) with 93,000 members nationwide., "This is ... makers of Praxis EMR, "Praxis is the only EMR ... it to other EMRs. Templates,turn doctors into technicians, forcing ...
... GREENWICH, Conn., March 4 Oracle Healthcare,Acquisition Corp. ... it has entered into an agreement with Precision ... the Agreement and Plan,of Merger, dated as of ... 2008 and,February 25, 2008 (as amended, the "Merger ...
... WASHINGTON and NEWARK, N.J., March 4 ,Cathedral Healthcare ... States $5.3,million, plus interest, to settle allegations that ... announced today., The settlement resolves allegations that ... Medicare patients in order,to obtain enhanced reimbursement from ...
... of veterinary medicine at Iowa State University, has identified ... disease, Immune-Mediated Retinopathy, or IMR, causes loss of function ... canines. , Grozdanic,s findings are published in the March ... Practice. , IMR is very similar to a previously ...
... New York man was,charged today in federal court with ... Sullivan; Warren T. Bamford, Special,Agent in Charge of the ... Special Agent in Charge of the Department of Health ... Resident,Agent in Charge of the Defense Criminal Investigative Service; ...
... March 4 Secretary of Health Dr.,Calvin B. ... Pediatric,Clinic in Warren to discuss Governor Edward G. ... to the hundreds of thousands of,uninsured adults through ... affordable insurance is critical to help prevent disease,successfully ...
Cached Medicine News:Health News:Template-Free Electronic Medical Record Wins AAFP User Satisfaction Survey. 2Health News:Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting 2Health News:Cathedral Healthcare System to Pay U.S. $5.3 Million to Resolve Allegations Involving Inflated Charges to Obtain Higher Medicare Reimbursement 2Health News:Iowa State University researcher identifies eye disease in canines 2Health News:Thomas Farina, Former Pharmaceutical Company District Manager, Charged With Obstruction of Justice 2Health News:Thomas Farina, Former Pharmaceutical Company District Manager, Charged With Obstruction of Justice 3Health News:Health Secretary Stops in Warren County on Statewide Tour to Call for Action on Health Insurance for All Pennsylvanians 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: